BIND Therapeutics to Present at 2015 Stifel Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that Andrew Hirsch, BIND’s president and chief executive officer, will present at the 2015 Stifel Healthcare Conference on Tuesday, November 17 at 8:45 a.m. ET.

Interested parties may access a live webcast of the presentation by visiting the BIND Therapeutics website at www.bindtherapeutics.com. The webcast will be archived on the BIND Therapeutics website for one week following the event.

About BIND TherapeuticsBIND Therapeutics is a clinical-stage nanomedicine company developing a pipeline of Accurins™, its novel targeted therapeutics designed to increase the concentration and duration of therapeutic payloads at disease sites while reducing exposure to healthy tissue. BIND is leveraging its Medicinal Nanoengineering® platform to develop a pipeline of Accurins targeting hematological and solid tumors and has a number of strategic collaborations with biopharmaceutical companies to develop Accurins in areas of high unmet need. BIND's lead drug candidate, BIND-014, is a prostate-specific membrane antigen (PSMA) -targeted Accurin that contains docetaxel, a clinically-validated and widely-used cancer chemotherapy drug. BIND is currently enrolling patients in a trial with BIND-014 for non-small cell lung cancer, or NSCLC, with KRAS mutations or squamous histology. In addition, BIND is enrolling patients in a clinical trial with BIND-014 for advanced cervical, bladder, head and neck and cholangio cancers. BIND is advancing BIND-510, its second PSMA-targeted Accurin drug candidate containing vincristine, a potent microtubule inhibitor with dose limiting peripheral neuropathy in its conventional form, through important preclinical studies to position it for an Investigational New Drug (IND) application filing with the U.S. Food and Drug Administration. BIND is also developing Accurins designed to inhibit PLK1 and KSP, both of which BIND believes are promising anti-mitotic targets that have been limited in the clinic due to systemic toxicity at or below therapeutic doses.

BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada) and Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals) to develop Accurins based on their proprietary therapeutic payloads and/or targeting ligands. BIND's collaboration with AstraZeneca has resulted in FDA clearance to begin clinical trials with the Aurora B Kinase inhibitor Accurin AZD2811, which the Company expects to be the second Accurin candidate to enter clinical development. BIND’s collaboration with Pfizer has resulted in the selection of an Accurin candidate that is entering IND-enabling studies.

For more information, please visit the Company's web site at www.bindtherapeutics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151110005539/en/

BIND Therapeutics:
Media
Jeff Boyle, 617-301-8816
[email protected]
or
Investors
Tom Baker, 617-532-0624
[email protected]

Source: BIND Therapeutics, Inc.

You May Also Be Interested In

• Arizona Governor Hobbs Attends Ceremony at Longroad Energy's Sun Streams Complex, Celebrating Expansion of Renewable Energy, Family Supporting Jobs and Community Benefits
• Alberto Castillo Injured in Truck Accident on Veterans Memorial Drive in Northwest Houston
• OPERATION HOPE CEO JOHN HOPE BRYANT'S LATEST BOOK, 'FINANCIAL LITERACY FOR ALL,' DEBUTS AT #12 ON USA TODAY BESTSELLER LIST